Retour sur lavenir.net
   BIOTALYS 1.998 € (+2,46 %)     D'IETEREN GROUP 178.600 € (-2,03 %)     AGEAS 77.500 € (-1,27 %)     SOFINA 267.600 € (-1,98 %)     ACKERMANS V.HAAREN 268.000 € (-0,30 %)     LOTUS BAKERIES 14 060.000 € (-0,14 %)     BPOST 0.885 € (-23,31 %)     KBC 117.400 € (+0,30 %)     DEME GROUP 164.200 € (-2,15 %)     ARGENX SE 815.800 € (+0,02 %)     CIE BOIS SAUVAGE 278.000 € (-1,42 %)     RECTICEL 12.360 € (+0,65 %)     AB INBEV 75.700 € (+0,05 %)     MELEXIS 53.400 € (+1,71 %)     SOLVAY 24.360 € (-0,73 %)     ONWARD MEDICAL 1.780 € (-0,89 %)     MONTEA 69.400 € (+1,17 %)     VAN DE VELDE 29.400 € (-0,34 %)     WDP 19.400 € (0,00 %)     ASCENCIO 52.900 € (-0,94 %)     TITAN S.A. 45.540 € (-0,83 %)     VIOHALCO 14.880 € (+3,33 %)     UCB 290.900 € (+0,24 %)     MATERIALISE 6.100 € (-3,94 %)     DECEUNINCK 2.425 € (-1,22 %)     AEDIFICA 65.650 € (+0,84 %)     ELIA GROUP 134.000 € (+0,30 %)     ORANGE BELGIUM 22.200 € (-0,45 %)     ACCENTIS 0.027 € (+3,92 %)     SHURGARD 25.550 € (+0,20 %)     KINEPOLIS GROUP 49.350 € (-2,28 %)     VGP 65.500 € (-1,50 %)     SYENSQO 76.700 € (-2,91 %)     BANQUP GROUP 0.850 € (-5,56 %)     AZELIS GROUP 11.750 € (-1,67 %)     BREDERODE 100.800 € (-0,79 %)     JENSEN-GROUP 74.400 € (+0,54 %)     NYXOAH 0.754 € (-1,57 %)     VASTNED 27.350 € (-0,73 %)     CMB.TECH 14.920 € (-1,97 %)     ENERGYVISION 17.180 € (-1,26 %)     UMICORE 18.470 € (-0,91 %)     BEKAERT 40.000 € (-1,60 %)     TESSENDERLO 17.620 € (-1,78 %)     TINC 10.400 € (-0,38 %)     FAGRON 24.200 € (-0,82 %)     RETAIL ESTATES 63.500 € (+0,47 %)     ONTEX GROUP 1.504 € (+1,08 %)     KBC ANCORA 94.200 € (+0,21 %)     COLRUYT 36.600 € (-1,03 %)     ECONOCOM GROUP 1.540 € (-2,53 %)     BELYSSE GROUP 0.350 € (-2,78 %)     CARE PROPERTY INV. 12.680 € (-0,31 %)     SOLVAC 86.000 € (-1,15 %)     WERELDHAVE BELGIUM 51.400 € (+1,98 %)     PROXIMUS 6.330 € (-0,71 %)     IBA 16.360 € (-1,56 %)     CENERGY 21.160 € (-0,09 %)     EVS 18.000 € (-0,99 %)     GIMV 49.350 € (0,00 %)  
   CSG 13.032 € (-3,85 %)     AKZO NOBEL 62.900 € (+0,51 %)     AVANTIUM(SUB) 0.250 € (-55,36 %)     PHILIPS KON 27.330 € (-0,65 %)     BE SEMICONDUCTOR 143.400 € (+1,77 %)     ASML HOLDING 1 283.600 € (+2,69 %)     AIR LIQUIDE 187.780 € (-1,02 %)     CELLECTIS 1.005 € (-4,10 %)     WOLTERS KLUWER 90.080 € (-2,53 %)     ADYEN 901.200 € (+0,97 %)     JACQUES BOGART 1.310 € (+15,93 %)     SAFRAN 295.500 € (-0,71 %)     BOUYGUES 42.290 € (-1,86 %)     STELLANTIS NV 4.019 € (+1,39 %)     VINCI 111.600 € (-1,20 %)     LVMH 408.750 € (-2,36 %)     ALPES (COMPAGNIE) 19.500 € (+1,46 %)     HERIGE 18.450 € (+2,22 %)     SAINT GOBAIN 74.100 € (-0,46 %)     AIRBUS 196.400 € (-1,25 %)     BUREAU VERITAS 29.950 € (-0,89 %)     ING GROEP N.V. 28.720 € (-1,73 %)     OCI 4.090 € (-0,29 %)     DSM FIRMENICH AG 109.800 € (-3,09 %)     RELX 36.180 € (-2,22 %)     BAM GROEP KON 12.610 € (+0,56 %)     FUGRO 8.480 € (-2,19 %)     X-FAB 4.840 € (+2,63 %)     SOITEC 94.340 € (+2,95 %)     AXA 44.680 € (-2,25 %)     SHELL PLC 44.740 € (-1,54 %)     MICHELIN 33.200 € (-0,42 %)     ABN AMRO BANK N.V. 41.000 € (-0,94 %)     ESSILORLUXOTTICA 193.800 € (+0,96 %)     IPSEN 158.700 € (-0,44 %)     HAL TRUST 169.600 € (-1,17 %)     NRJ GROUP 5.860 € (-2,33 %)     HAVAS 17.850 € (-2,19 %)     EURONEXT 170.000 € (-2,47 %)     SAMSE 113.500 € (-0,44 %)     REXEL 34.450 € (+0,17 %)     CAPGEMINI 126.900 € (-2,76 %)     LAKEFRONT BIOTHER. 29.620 € (-1,92 %)     ENGIE 24.200 € (+0,79 %)     ASM INTERNATIONAL 651.000 € (+2,39 %)     SARTORIUS STED BIO 225.800 € (+0,71 %)     SIDETRADE 204.500 € (+0,74 %)     ADP 117.100 € (-0,59 %)     ABIVAX 77.150 € (-0,64 %)     UNILEVER 59.310 € (-1,79 %)     CREDIT AGRICOLE 15.840 € (+0,38 %)     PERNOD RICARD 71.140 € (-0,73 %)     STMICROELECTRONICS 37.635 € (+1,54 %)     FLEURY MICHON 23.900 € (+0,84 %)     IMERYS 25.400 € (-1,17 %)     PLANISWARE 24.900 € (-1,39 %)     EUROFINS SCIENT. 88.640 € (-0,45 %)     EURAZEO 49.380 € (-2,22 %)     ALTAREA 74.100 € (-0,94 %)     TIKEHAU CAPITAL 16.720 € (-0,24 %)  
News Réglementées
07/09/2026 13:00

Clearway Capital rejects GZO's proposed composition agreement

Lemongrass Communications AG / Key word(s): Legal Matter
Clearway Capital rejects GZO's proposed composition agreement

07.09.2026 / 13:00 CET/CEST


Media Release

Clearway Capital urges creditors to reject GZO's proposed composition agreement

Zurich, 7 September 2026 – Clearway Capital Partners ICAV (“Clearway”), a creditor of GZO AG Spital Wetzikon (“GZO”) leading the GZO Creditor Group, announces that it will vote against the composition agreement (Nachlassvertrag) to be put to creditors at the assembly expected in the second half of October 2026, and urges all creditors to do the same.

Creditors are being asked to approve the inferior of two offers. GZO’s plan, built around thurmed AG as strategic investor, delivers just CHF 70.1 million in cash, equal to 29.0% of claims. The headline recovery of 39.3–47.5% materially overstates the economic value being offered, as it relies on deferred and highly uncertain components: 10.3% is stretched over ten years without interest or security; a further 8.2% depends entirely on the outcome of GZO’s dispute with Steiner; and the additional EBITDA-linked payment cannot be quantified as it requires GZO to achieve an 8% operating margin, far above the 5.1% delivered in 2025. Clearway therefore assigns no value to the contingent components and only minimal present value to the deferred payment.

Creditors were denied the opportunity to compare the proposal against a materially better alternative, which was rejected by the company. On 29 July 2026, Infracore SA made a binding, fully financed offer of CHF 55 million in cash for GZO's real estate, payable upon confirmation of the composition agreement. Together with the CHF 96.5 million of cash and securities in GZO's audited 2025 accounts, Clearway estimates that this offer could have supported an immediate cash recovery of up to 60% - roughly double what creditors are now being asked to accept.

GZO terminated the Infracore offer on the basis of an assessment by its financial adviser PwC, which has not been shared with creditors. It is not the first time creditors have been asked to accept an advisor's conclusion in place of the underlying analysis. The bankruptcy comparison used to sell the current plan rests on a liquidation status that values GZO's entire fixed-asset base at CHF 12.0 million, and the hospital parcel itself at zero. A binding offer has now put a market price on that same real estate: CHF 55 million, more than four times the figure creditors were given.

Importantly for all creditors, this vote will not be decided by headcount alone. Under Article 305 SchKG, creditors holding just over one-third of total claims can block the agreement regardless of the number of heads voting in favor. At the September 2025 assembly, creditors representing some CHF 165 million of claims, approximately two-thirds of the total, were already aligned with Clearway's position. It is therefore of the utmost importance that as many creditors as possible participate in the assembly and cast their vote. Clearway is confident that the agreement will not pass in its current form and urges all creditors to participate, either in person or via proxy.

“Creditors are being asked to write off 70% of their claims to recapitalize a hospital in which they will receive no ownership, no security and no interest on the amounts still owed to them. At the same time, GZO rejected a substantially superior offer without giving creditors the opportunity to consider it,” said Gianluca Ferrari, founder of Clearway Capital.

“This is not a plan based on what GZO can afford to pay. It is a plan based on how little GZO believes creditors can be persuaded to accept,” he added.

Clearway will provide creditors with further updates ahead of the assembly, and practical assistance to any creditor wishing to vote against the agreement. Clearway is also evaluating all options at its disposal to protect creditor interests, including with regard to the decisions that have brought creditors to this point.

Creditors are invited to contact Clearway directly with questions regarding the exercise of their vote.

 

Contact for Media:
Lemongrass Communications AG

susanne.muehlemann@lemongrass.agency
+41 79 223 70 81

Contact for Investors:

contact@gzo-bondholder.ch

About Clearway Capital:

Clearway Capital Partners is an alternative investment fund that invests in special situations in Western European markets where seeks to unlock value through responsible ownership. With a focus on protecting investor rights and ensuring fair treatment of stakeholders, Clearway Capital actively advocates for transparent and equitable corporate practices.

 


Additional features:

File: Clearway_GZO_MM_07_09_26_E


End of Media Release
View original content: EQS News


2394934  07.09.2026 CET/CEST

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière